Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that
affects patients' function, quality of life, and ability to tolerate treatment. In certain patients …

The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …

The scope of dermatologic adverse events to ibrutinib has not been systematically
described. We sought to determine the incidence and severity of ibrutinib-associated …

Background Advances in molecular biology and genetics have contributed to breakthrough
treatments directed at specific pathways associated with the development of cancer. Small …

Ibrutinib is a Burton tyrosine kinase inhibitor (BTKi) approved for the treatment of several
hematologic malignancies. Analyze skin adverse events (SAE). All the patients treated with …

B‐cell chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the United
States, and its diagnosis can have many dermatologic implications. For one, the cutaneous …

Oral mucositis (OM) is one of the most common adverse events associated with
antineoplastic drug treatment. Studies on the risk of antineoplastic drug-induced OM and its …

The incidence of primary central nervous system lymphoma (PCNSL) has steadily
increased, particularly in elderly patients. Although highly responsive to first-line …

Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has revolutionised the treatment for
multiple lymphoproliferative disorders and chronic graft versus host disease [1]. It is explored …